On October 5, 2022 NeoImmuneTech, Inc. (NIT or "NeoImmuneTech"), a clinical-stage T cell-focused biopharmaceutical company, reported it will present development progress of its main asset, NT-I7 (efineptakin alfa), across five presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting, to be held in Boston, November 8-12, 2022 (Press release, NeoImmuneTech, OCT 5, 2022, View Source [SID1234621755]). These include 1 oral presentation, and 4 poster displays.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

NIT presentations at the 2022 SITC (Free SITC Whitepaper) Annual Meeting:

Primary Author

Abstract Title

Presentation Details

Naing, A

NT-I7, a long-acting IL-7, plus
pembrolizumab favors CD8 T-cell
infiltration in liver metastases of heavily pre-treated,
immunologically cold, MSS-colorectal and
pancreatic cancer

• Abstract #657

• Oral presentation

• Session 213: Next-Generation Cytokine Therapy

• Nov 11, 2022, 5:20 pm – 5:35 pm, EST

Campian, J

A phase I/II study evaluating the safety and
efficacy of a novel long-acting interleukin-7,
NT-I7, for patients with newly diagnosed
high-grade gliomas after chemoradiotherapy

• Abstract #624

• Nov 11, 2022

Kang, H

NT-I7 for the treatment of locally recurrent
squamous cell carcinoma of head and neck
undergoing salvage surgery: A clinical trial in
progress.

• Abstract #679

• Nov 10, 2022

Phoon, Y

NT-I7, a novel long-acting interleukin-7,
improves engraftment of patient immune
cells and efficacy of anti-PD-1 therapy in a
preclinical humanized melanoma model

• Abstract #849

• Nov 10, 2022

Lee, S

Redirecting IL-7-induced bystander tumor-
infiltrating lymphocytes by bispecific T-cell
engager augments antitumor response

• Abstract #837

• Nov 10, 2022

About NT-I7 (efineptakin alfa) (rhIL-7-hyFc)

NT-I7 (efineptakin alfa) is the only clinical-stage long-acting human IL-7 and is being developed in oncologic and immunologic indications, where T cell amplification and increased functionality may provide clinical benefit. IL-7 is a fundamental cytokine for naïve and memory T cell development and sustaining immune response to chronic antigens (as in cancer) or foreign antigens (as in infectious diseases). NT-I7 exhibits favorable PK/PD and safety profiles, making it an ideal combination partner. NT-I7 is being studied in multiple clinical trials in solid tumors and as vaccine adjuvant. Studies are being planned for testing in hematologic malignancies, additional solid tumors and other immunology-focused indications.

On October 5, 2022 Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) ("Curaleaf" or the "Company"), a leading international provider of consumer products in cannabis, reported the completion of its previously announced acquisition of Tryke Companies ("Tryke") (dba as Reef Dispensaries), a privately held vertically integrated, multi-state cannabis operator (Press release, Curaleaf Holdings, OCT 5, 2022, View Source [SID1234621754]). With the close of the transaction, Curaleaf’s national footprint has reached 29 cultivation sites and 144 dispensaries nationwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Boris Jordan, Founder and Executive Chairman of Curaleaf, stated, "We are pleased to welcome Tryke to the Curaleaf family as we expand our operations and bolster our competitive position in three key growth markets. This strategic transaction expands our U.S. presence and yields meaningful benefits for all of our stakeholders. The acquisition is immediately accretive to our EBITDA margins and free cash flow generation."

Matt Darin, CEO of Curaleaf, said, "As we continue to unite the strength of our brands, products and cultivation channels to lead the industry, we’re excited to join forces with Tryke to deliver additional value for our customers and retailers in Arizona, Nevada and Utah. This deal represents a significant opportunity with strong long-term growth potential, and we are now strategically positioned us to accelerate our growth in the West."

Tryke Companies Highlights:

Four retail dispensaries in Las Vegas, Sparks, and Sun Valley, Nevada; two retail dispensaries in Phoenix, Arizona.
Expansive product offering including a wide variety of in-house and third-party flower, concentrates, vape cartridges, edibles, topicals and CBD products.
Extensive portfolio of processing licenses with 30,000 square feet of cultivation; capacity to expand to 80,000 square feet over the next three years.
Transaction Details:

The transaction consideration includes an initial payment at closing of US$10 million in cash and 2.7 million shares, and additional cash and shares consideration of US$75 million and 16.5 million Subordinate Voting Shares, to be paid in three installments on the first, second and third anniversaries of the closing, for a total consideration of US$181 million. Contingent consideration of up to 1 million Subordinate Voting Shares may be paid in 2023 based on the business exceeding certain EBITDA targets for the year 2022.

On October 5, 2022 I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, reported that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022 (Press release, I-Mab Biopharma, OCT 5, 2022, View Source [SID1234621753]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Full text of the abstracts will be released on the SITC (Free SITC Whitepaper) website at 8:00 a.m. ET on Monday, November 7, 2022, and the posters will be available on the Company’s website on November 12, 2022.

About CD47 and Lemzoparlimab

CD47 is a cell surface protein over-expressed in a wide variety of cancers and can act to protect tumors by delivering a "don’t eat me" signal to otherwise tumor-engulfing macrophages. CD47 antibody blocks this signal and enables macrophages to attack tumor cells. However, development of CD47 antibody as a cancer therapy has been hampered by its hematologic side effects, such as severe anemia, caused by natural binding of CD47 antibody to red blood cells. Scientists at I-Mab discovered a novel CD47 antibody, lemzoparlimab, that is designed to target tumor cells while exerting a minimal untoward effect on red blood cells.

Multiple clinical studies of lemzoparlimab are ongoing to explore indications in treating patients with myelodysplastic syndrome (MDS), acute myelocytic leukemia (AML), non-Hodgkin’s lymphoma (NHL), and advanced solid tumors in combination with chemotherapy and immune checkpoint inhibitors.

About Uliledlimab

Uliledlimab (also known as TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine. Adenosine in turn binds to adenosine receptors on relevant immune cells and inhibits anti-tumor immune responses in tumor microenvironment. Uliledlimab is expected to offer clinical benefit by suppressing tumor growth in concert with checkpoint therapies such as PD-(L)1 antibodies. Uliledlimab is effective in anti-tumor activities through a unique intra-dimer binding, leading to differentiated and favorable functional properties as evident in preclinical studies.

On October 5, 2022 KaliVir Immunotherapeutics, Inc., a biotech company developing cutting-edge, multi-therapeutic oncolytic viral immunotherapy programs, reported that it will be presenting data on its product candidate VET3-TGI at the 37th Annual Meeting of the Society for Immunology of Cancer (SITC) (Free SITC Whitepaper), taking place November 8-12, 2022 in Boston, Massachusetts (Press release, KaliVir Immunotherapeutics, OCT 5, 2022, View Source [SID1234621752]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VET3-TGI is based on KaliVir’s unique Vaccinia Enhanced Template (VET) platform, capable of generating potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread. VET3-TGI incorporates modifications granting the expression of CXCR3, IL-12 and a TGF-β inhibitor, allowing for efficient trafficking to the tumor, activation of anti-tumor immune responses and inhibition of immunosuppressive activity.

On October 5, 2022 Immunitas Therapeutics ("Immunitas"), a precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, reported they will present preclinical data on lead program IMT-009, a fully human monoclonal antibody against a novel immuno-oncology target CD161, at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 37th Annual Meeting, held both virtually and in Boston from November 8-12, 2022 (Press release, Immunitas Therapeutics, OCT 5, 2022, View Source [SID1234621751]). The company also announced the addition of Juliana Idoyaga, Ph.D., to its Scientific Advisory Board.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The SITC (Free SITC Whitepaper) presentation will demonstrate the potential of IMT-009 as a novel cancer immunotherapy to treat solid tumors and hematological malignancies.

Poster Presentation Details for IMT-009:
Title: Anti-CD161 antibody IMT-009 is a novel immunotherapeutic agent that reinvigorates T and NK cell function and anti-tumor efficacy through blocking interaction of CD161 with its ligand CLEC2D
Abstract Number: 235020
Date/Time: All poster presentations are made available by the conference on November 10, 2022.

"We are excited to present the preclinical data which supported the IND filing of IMT-009 at SITC (Free SITC Whitepaper) 2022 and are delighted to welcome Juliana to our Scientific Advisory Board at this pivotal time in Immunitas’ journey," said Seng-Lai "Thomas" Tan, Ph.D., Chief Scientific Officer of Immunitas Therapeutics. "As we progress IMT-009 into the clinic based on the data showing a potential for efficacy in various types of tumors, we will also continue advancing our pipeline of next generation differentiated immunotherapies. Juliana’s vast expertise in the basic biology of dendritic cells and their applications towards therapeutics and shared passion for discovering possible applications of novel immuno-oncology therapeutics is a great addition as we expand our pipeline."

Dr. Idoyaga is currently an Assistant Professor in the Department of Microbiology and Immunology at Stanford University School of Medicine, where she is leading research on dendritic cell subset tissue localization, function and the potential applications of dendritic cell-targeted vaccines and therapies.

Dr. Idoyaga received her B.S. in Biology and Immunology from the Buenos Aires University in Argentina. She then completed her Ph.D. in Immunology and Biomedical Sciences with honors at the National Autonomous University of Mexico. She performed her postdoctoral training in the laboratory of Cellular Physiology and Immunology at The Rockefeller University before joining Stanford University’s faculty and serving as the chair of the CDIII (Community, Diversity and Inclusion in Immunology) Committee. During her career, Dr. Idoyaga has earned many awards including NIH Pathway to Independence Award, the NIH Director’s New Innovator Award, Baxter Foundation Faculty Scholar Award, and the Gabilan Faculty Fellow Award.

The SITC (Free SITC Whitepaper) poster presentation will be available on the Immunitas Therapeutics website on November 10, 2022.

About IMT-009

IMT-009 is an Fc-attenuated monoclonal antibody that binds with high affinity and selectivity to CD161, a receptor that is broadly expressed on NK and a subset of memory T cells, blocking interactions between the receptor and its cognate ligand, CLEC2D, which is expressed on the surface of both cancer cells and immune cells. Preclinical data confirm that CD161 blockade with IMT-009 results in enhanced anti-tumor activity. IMT-009 is anticipated to begin enrollment for a Phase 1/2a clinical trial in Q4 2022 for use as a monotherapy and combination treatment for solid tumor and hematological malignancies. The Phase 1 study is designed to evaluate the safety, tolerability, pharmacodynamic biomarkers, and preliminary efficacy of IMT-009 as well as identify the Recommended Phase 2 Dose (RP2D). The trial will then transition into Phase 2 with multiple expansion cohorts to assess the safety and efficacy of IMT-009 alone or in combination with another antineoplastic agent.